Biochemical markers: The road map for the diagnosis of nonalcoholic fatty liver disease

American Journal of Clinical Pathology

Volumn 127, Issue 1, 2007, Pages 20-22

  Ahmed, Mohamed H ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Biochemical marker; Fatty liver; Invasive and noninvasive investigations

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASCORBIC ACID; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID; ADIPONECTIN; ADIPONECTIN, HUMAN; BIOLOGICAL MARKER; TRANSFERRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE MARKER; FATTY ACID BLOOD LEVEL; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; REVIEW; ARTICLE; BLOOD; GLUCOSE INTOLERANCE;

ADIPONECTIN; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GAMMA-GLUTAMYLTRANSFERASE; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; TRANSFERRIN;

EID: 34249053560     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/JXWUM661T8VT1ETX     Document Type: Review

References (14)

1. Ahmed MH, Byrne CD. Non-alcoholic steatohepatitis. In: Byrne CD, Wild S, ed. Metabolic Syndrome. Chichester, England: Wiley & Sons; 2005:279-303.
2. Ahmed MH. Invasive and non-invasive investigations for non-alcoholic steatohepatitis: the benefit of histology [letter]. Scand J Gastroenterol. 2005;40:1260.
3. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513-1517.
4. Luyckx FH, Scheen AJ, Desaive C, et al. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. J Diabetes Metab. 1998;24:355-361.
5. Haukeland JW, Konopski Z, Linnestad P, et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2005;40:1469-1477.
6. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-121.
7. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
8. Holt HB, Wild SH, Wood PJ, et al. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia. 2006;49:141-148.
9. Pirro M, Mauriege P, Tchernof A, et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis. 2002;160:377-384.
10. Widjaja A, Morris RJ, Levy JC, et al. Within- and between-subject variation in commonly measured anthropometric and biochemical variables. Clin Chem. 1999;45:561-566.
11. Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:113-118.
12. Ahmed MH. The dilemma of invasive and non-invasive investigations for adult and paediatric non-alcoholic fatty liver disease: has the time come for a new biochemical marker [letter]? Clin Chem Lab Med. 2006;44:508-509.
13. Mardini H, Record C. Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy? Ann Clin Biochem. 2005;42:441-447.
14. Ohtsuka T, Tsutsumi M, Fukumura A, et al. Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. Alcohol Clin Exp Res. 2005;29(12 suppl):236S-239S.